Your voice may reveal hidden liver risks
NCT ID NCT05425316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether speech features—like how people sound and what they say—can help detect or predict confusion caused by liver disease (hepatic encephalopathy). Researchers recorded speech tasks from 251 participants with cirrhosis and tracked their thinking skills and confusion episodes over time. The goal is to find a simple, non-invasive way to monitor brain health in people with liver problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
251 people
The number who actually took part.
- Started
-
Oct 2021
- Finished
-
Jul 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Study population consists of adult outpatients who are evaluated at the University of Michigan Hepatology Clinic.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for Patients with Cirrhosis: * Cirrhosis, as diagnosed by imaging, elastography, biopsy, or decompensation * Able to provide informed consent in English Exclusion Criteria for Patients with Cirrhosis: * Neurodegenerative disorder (other than hepatic encephalopathy) including Alzheimer's disease and dementia * Prior stroke or Transischemic Attack (TIA) * English not primary language for communication Inclusion Criteria for Patients without Cirrhosis: * Able to provide informed consent in English * Fibroscan with stiffness \<7 kPa Exclusion Criteria for Patients without Cirrhosis: * Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \>5 times the upper limit of normal in the last year * History of cirrhosis by imaging or histology or clinical decompensation * Neurodegenerative disorder (other than hepatic encephalopathy) including Alzheimer's disease and dementia * Prior stroke or TIA
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cirrhosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan Hepatology and Transplant Clinic
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria in a capsule: a new attempt to calm a brain complication of cirrhosis
- Sound waves may replace the needle in liver scarring tests
- Ultrasound may replace invasive test for dangerous liver complication
- Could a wearable zapper quiet cirrhosis pain without drugs?
- A needle through the gut could replace the standard liver pressure test
- Could common heartburn drugs raise brain risk after liver shunt?